Drug Target Review

JULY 1, 2024

He is spearheading the scientific and clinical development and fundraising of South Rampart Pharma and technology development efforts. Dr Hernan Bazan received a BS in molecular biology from Vanderbilt University and has spent two years in medical school as a Howard Hughes Medical Institute (HHMI) Research Scholar at the NIH.

Treatment 59

Treatment Clinical Trials Therapies Molecular Biology 59

The Pharma Data

NOVEMBER 19, 2020

Additionally, Raffaele Baffa was named chief medical officer of Ziopharm. Previously, Baffa was Therapeutic Area Head of Oncology, Global Clinical Development for Shire. Q State – Steven Hyman and Mathew Might joined the Q State Biosciences Board of Directors as independent directors.

Laboratories 52

Laboratories Research Laboratories Science Organic Chemistry 52

The Pharma Data

DECEMBER 15, 2020

In late 2020, the effort received $200,000 in seed funding from the Baker Department of Cardiometabolic Health at the University of Melbourne’s medical school. Scientists will be testing a drug class targeting the C-reactive protein (CRP) marker of acute inflammation in the body.

Disease 52

Disease Clinical Trials Small Molecule Trials 52

Drug Target Review

AUGUST 28, 2024

Available from: [link] About the author Cliff Brass, MD PhD FAASLD, Chief Medical Officer at Resolution Therapeutics Cliff Brass is an expert in clinical development with special expertise in liver disease and over 25 years of experience in pharma. Reference 1 Brennan P et al., J Hep, 2024 (EASL ILC 2024 Abstract #LBP-007).

Therapies 116

Therapies Disease Engineering Medical Schools 116

Drug Target Review

JANUARY 15, 2024

Previously, as a member of the faculty at Harvard Medical School , Dr Kavanagh was engaged in preclinical and clinical development of cellular immunotherapy and products. References Robinson R, McMurran C, McCully M, Cole D. Engineering soluble T-cell receptors for therapy.

Engineering 110

Engineering DNA Virus Immune Response 110

The Pharma Data

SEPTEMBER 1, 2020

In the PIONEER clinical development programme, Rybelsus showed significantly greater HbA1c reduction at one year, with the additional benefit of consistent weight reduction, versus treatments used in the UK: sitagliptin, empagliflozin and liraglutide, Novo noted. “GLP-1

Medical Schools 52

Medical Schools Treatment Clinical Development Disease 52

The Pharma Data

NOVEMBER 1, 2020

Trial facilitated with coll a boration of Harvard Medical School and one of the world’s top Neurologist, Dr. Howard Weiner. Clinical Data Expected by End of Year. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) in clinical development in the world.

Clinical Trials 40

Clinical Trials Trials Medical Schools Hospitals 40

The Pharma Data

JANUARY 7, 2021

ONC201 is currently in a registrational clinical trial for recurrent H3 K27M-mutant glioma and a confirmatory response rate assessment is expected in 2021. FACP and all the employees at Oncoceutics in developing a therapy for patients for which there is no available treatment.”. scientific founder Wafik El-Deiry, M.D.,

Clinical Trials 52

Clinical Trials Small Molecule Trials Therapies 52

The Pharma Data

APRIL 12, 2022

vice president and global head of oncology clinical development at AbbVie. “Data obtained from this exploratory analysis holds promise for potential future clinical research,” said Jacqueline S. Dana-Farber Cancer Institute, assistant professor of medicine at Harvard Medical School. Garcia, M.D.,

Medical Schools 52

Medical Schools Trials Disease Clinical Development 52

The Pharma Data

JANUARY 3, 2021

The clinical study was completed in collaboration with scientific teams at the Harvard Medical School (Boston, USA), Santa Casa de Misericórdia de Santos Hospital (Santos, Brazil) and INTRIALS, a world-class, full-service Latin American CRO based in São Paulo, Brazil. . NEW YORK and LONDON, Jan.

Clinical Trials 40

Clinical Trials Science Treatment Trials 40

The Pharma Data

JUNE 25, 2021

“With the results of KEYNOTE-564, pembrolizumab is the first immunotherapy to show a clinical benefit in the adjuvant setting in kidney cancer,” said Dr. Toni K. Choueiri, director of the Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and professor of medicine at Harvard Medical School. “It

Disease 52

Disease Therapies Treatment Medical Schools 52

The Pharma Data

OCTOBER 15, 2020

Prior to his corporate experience, he was an instructor at the Harvard Medical School in the Endocrine unit. OncoSec Medical – Sanda Aung was named chief clinical development officer for OncoSec Medical Incorporated. She was also CSO at Adjuvant Partners.

Pharmaceuticals 52

Pharmaceuticals Clinical Pharmacology Medical Schools Therapies 52

Drug Target Review

DECEMBER 28, 2023

His research unveiled the critical role of Fc receptors and the tumour microenvironment in the mechanism of action of anti CTLA-4 antibodies, and he is an inventor of several key patents supporting the clinical development of antibodies targeting immune checkpoints.

Bioinformatics 105

Bioinformatics Immune Response DNA Vaccine 105

The Pharma Data

MARCH 17, 2021

Tolaney, MD, MPH, Harvard Medical School, Dana-Farber Cancer Institute. Across the clinical development program, deaths due to venous thromboembolism have been reported. Monitor patients for signs and symptoms of venous thrombosis and pulmonary embolism and treat as medically appropriate.

Trials 52

Trials Therapies Treatment Disease 52

The Pharma Data

JANUARY 24, 2021

” Professor Aaron LeBeau ( University of Minnesota Medical School, Department of Pharmacology): “Determining the structure of protein complexes by x-ray crystallography can often be a taxing process requiring months to years to get a structure.

Research 40

Research Virus Medical Schools Government 40

The Pharma Data

NOVEMBER 18, 2021

Choueiri, director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, and professor of drug, Harvard Medical School. With this FDA blessing, pembrolizumab may address a critical unmet treatment need and has the implicit to come a new standard of care in the adjuvant setting for meetly named cases.”.

FDA Approval 52

FDA Approval FDA Therapies Treatment 52

Drug Target Review

MARCH 20, 2025

This potential breakthrough could transform both drug discovery and clinical treatment strategies, with the possibility of enhancing patient safety and improving outcomes in thrombotic conditions like atrial fibrillation. NYSE: MRK), which included leadership roles in early and late clinical development and cardiovascular discovery.

Therapies 52

Therapies Trials Clinical Development FDA 52